Nine natural compounds—rapamycin, berberine, resveratrol, pterostilbene, quercetin, EGCG, fisetin, apigenin, and curcumin—demonstrate senomorphic and senolytic properties that specifically target aging mechanisms in respiratory tissue. These compounds address cellular senescence by modulating the senescence-associated secretory phenotype (SASP) that drives chronic lung inflammation and tissue dysfunction. Preclinical models show efficacy against COPD, idiopathic pulmonary fibrosis, ARDS, and respiratory infections through overlapping pathways involving inflammation reduction, immune dysfunction correction, and oxidative stress mitigation. This represents a potentially transformative approach to respiratory health in aging populations. Unlike conventional treatments that manage symptoms, these natural senotherapeutics target fundamental aging mechanisms—cellular senescence, inflammaging, and immunosenescence—that make lungs particularly vulnerable to age-related decline. The therapeutic potential is significant given that respiratory diseases are leading causes of mortality in older adults. However, clinical translation faces substantial hurdles including poor bioavailability, undefined optimal dosing, and delivery challenges. While promising, this remains largely preclinical science requiring rigorous human trials to validate efficacy and safety profiles before clinical application.